218 related articles for article (PubMed ID: 2459854)
21. [Possibilities and limits of the use of interferons in the clinic].
Ludwig CU
Schweiz Med Wochenschr; 1989 Nov; 119(44):1539-43. PubMed ID: 2479977
[TBL] [Abstract][Full Text] [Related]
22. [Antineoplastic effects of interferons].
Shimoyama M
Nihon Rinsho; 1986 Feb; 44(2):395-402. PubMed ID: 2422409
[No Abstract] [Full Text] [Related]
23. [Alpha interferons--new therapeutic modalities].
Bajcetić M; Zigon N; Samardzić R; Beleslin DB
Med Pregl; 1998; 51(3-4):135-9. PubMed ID: 9611956
[TBL] [Abstract][Full Text] [Related]
24. Interferons in oncology.
Woll PJ; Pettengell R
Br J Clin Pract; 1997 Mar; 51(2):111-5. PubMed ID: 9158255
[TBL] [Abstract][Full Text] [Related]
25. [Interferons in the treatment of hematological diseases].
Jantunen E; Nousiainen T
Duodecim; 1998; 114(12):1240-7. PubMed ID: 11524770
[No Abstract] [Full Text] [Related]
26. The alpha interferons: clinical overview.
Spiegel RJ
Semin Oncol; 1987 Jun; 14(2 Suppl 2):1-12. PubMed ID: 3296210
[TBL] [Abstract][Full Text] [Related]
27. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
28. [Indications, technique and risks in bone marrow transplantation in adulthood].
Heyll A; Söhngen D; Minning H; Meckenstock G; Aul C; Schneider W
Praxis (Bern 1994); 1996 Mar; 85(12):378-86. PubMed ID: 8643901
[TBL] [Abstract][Full Text] [Related]
29. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
Bremer K
J Cancer Res Clin Oncol; 2002 Nov; 128(11):603-9. PubMed ID: 12458340
[TBL] [Abstract][Full Text] [Related]
30. Leukocyte interferon as a possible biological response modifier in lymphoproliferative disorders resistant to standard therapy.
Clark RH; Dimitrov NV; Axelson JA; Charamella LJ
J Biol Response Mod; 1984 Dec; 3(6):613-9. PubMed ID: 6512561
[TBL] [Abstract][Full Text] [Related]
31. [Efficacy of recombinant interferon alpha-2 in 34 patients with hairy cell leukemia. Effect of splenectomy and dosage reduction results of therapy].
Frey B; Hofmann V; Cavalli F; Fehr J; Kroner T; Nesthus I; Schwarzmeier J
Schweiz Med Wochenschr; 1988 Oct; 118(41):1468-75. PubMed ID: 3238389
[TBL] [Abstract][Full Text] [Related]
32. [Interferon-alpha in therapy of malignant hemoblastoses].
Schuler M; Aulitzky WE; Schneller F; Peschel C; Huber C
Internist (Berl); 1995 Dec; 36(12):1133-8. PubMed ID: 8567218
[No Abstract] [Full Text] [Related]
33. Alpha-interferon treatment of cutaneous T cell lymphoma and chronic lymphocytic leukemia.
Foon KA; Bunn PA
Semin Oncol; 1986 Dec; 13(4 Suppl 5):35-9. PubMed ID: 3541217
[TBL] [Abstract][Full Text] [Related]
34. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
[TBL] [Abstract][Full Text] [Related]
35. Alfa interferon: combinations with other antineoplastic modalities.
Bonnem EM
Semin Oncol; 1987 Jun; 14(2 Suppl 2):48-60. PubMed ID: 3296212
[TBL] [Abstract][Full Text] [Related]
36. [Interferon-alpha therapy in non-Hodgkin's lymphoma].
Fridrik MA
Wien Med Wochenschr; 1993; 143(16-17):429-34. PubMed ID: 8273367
[TBL] [Abstract][Full Text] [Related]
37. Interferon-alpha: current status and future promise.
Bonnem EM; Spiegel RJ
J Biol Response Mod; 1984 Dec; 3(6):580-98. PubMed ID: 6392483
[No Abstract] [Full Text] [Related]
38. Interferon in the treatment of multiple myeloma and the non-Hodgkin's lymphomas.
Wagstaff J; Scarffe JH; Crowther D
Cancer Treat Rev; 1985 Dec; 12 Suppl B():39-44. PubMed ID: 2421896
[No Abstract] [Full Text] [Related]
39. [Malignant hematologic diseases. Diagnosis and treatment. A clearing report].
Birgens H; Christensen BE; Hansen NE; Jensen MK; Junker K; Jørgensen FS; Nielsen JL; Nissen NI
Ugeskr Laeger; 1991 Jun; 153(23):1638-47. PubMed ID: 2058026
[TBL] [Abstract][Full Text] [Related]
40. High dose alpha-2-recombinant interferon in the treatment of malignant lymphoproliferative diseases. A pilot study.
Opat P; Drbal J; Vyzula R
Neoplasma; 1989; 36(4):489-94. PubMed ID: 2770934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
